Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price objective hoisted by stock analysts at Leerink Partners from $146.00 to $148.00 in a research note issued to investors on Wednesday,MarketScreener reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Partners’ price objective would indicate a potential downside of 4.50% [...]
93pts. Had a couple of requests for this during the week, so here it is! 🌱 Vineyard: Lower Tintara, Kays Rd - originally planted by Thomas Hardy in the 1880s. 🪨 Soils: Maslin Sands, laid down ... Read Full Article →
New Delhi: Old Delhi's 13 protected monuments and their parts including Red Fort's Diwan-i-Aam, Mumtaz Mahal, Diwan-i-Khas, Delhi Gate, Ajmeri Gate an. Read Full Article →
New Delhi: Over a decade after a govt bank was allegedly duped of over Rs 4.1 crore in southwest Delhi's Najafgarh, the Central Bureau of Investigatio. Read Full Article →
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but it also means giving up some upside when risk appetite shifts toward early-stage biotech companies. Read Full Article →
